Ceftazidime: comparative in-vitro study.
Ceftazidime showed moderate activity against Staphylococcus aureus and a high activity against Haemophilus influenzae and the streptococci except against the enterococci. Ceftazidime inhibited 90% of the 830 Enterobacteriaceae tested at a concentration of 0.5 mg/l and 99% at 8 mg/l, an activity very similar to that of cefotaxime. Against Pseudomonas spp. ceftazidime proved to be the most active beta-lactam antibiotic studied. It inhibited 67% of the 141 Ps. aeruginosa strains at 2 mg/l, 84% at 4 mg/l, 98% at 8 mg/l and 100% at 16 mg/l. The inhibitory and the bactericidal concentrations were very close and there was only a minor effect of the inoculum. Ceftazidime retained its high activity against microorganisms with acquired as well as with natural resistance to other beta-lactam antibiotics.
Verbist
L
L
Diagnostic Microbiology Laboratory, St Rafaël Hospital, University of Leuven, B-3000 Leuven, Belgium.
Verhaegen
J
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D002228:Carbenicillin / Q000494:pharmacology; D002439:Cefotaxime / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology*; D002444:Cefuroxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D002512:Cephalothin / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002442:Ceftazidime; D002228:Carbenicillin; D002439:Cefotaxime; D002444:Cefuroxime; D002512:Cephalothin